Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

<<< 17th International Myeloma Workshop

Related Content:

International Myeloma Society Annual MeetingConferenceHematologic Oncology
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL